F. Xavier Palomer Tarridas
The researcher F. Xavier Palomer Tarridas graduated in Biology in 1995 from the University of Barcelona. In 1998, after receiving a grant from the Ministry of Education and Science, the Researcher began his doctoral studies at the Institute of Molecular Biology in Barcelona (IBMB-CSIC), obtaining his title of Doctor of Biology by the same University of Barcelona in 2002. During that period, he spent a four-month pre-doctoral stay at the Plant Research International technology center in Wageningen (Netherlands), thanks to a BAC grant awarded by UNESCO.
Between 2002 and 2005, the Researcher spent a post-doctoral stay at the current Biomedical Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona, where he began the study of metabolic diseases such as type 2 diabetes (DM2) and obesity, but also of autoimmune origin (type 1 diabetes, DM1), both from a clinical and basic perspective.
In 2006, he obtained a post-doctoral contract from the Juan de la Cierva Program (Ministry of Education and Science) to join the research group of Dr. Manuel Vázquez Carrera, of the Department of Pharmacology, Toxicology and Therapeutic Chemistry of the Faculty of Pharmacy and Food Sciences of the University of Barcelona. Between 2008 and 2015 he pursued these post-doctoral studies in the same Department, thanks to the granting of a post-doctoral contract by CIBERDEM (Carlos III Health Institute). In this center, the Researcher continued the study of metabolic diseases with an inflammatory background (obesity and DM2), also initiating research within the line of diabetic cardiomyopathy, which is currently still the subject of his main line of research.
Since 2015 he has been an Associate Professor at the University of Barcelona in the same Department of Pharmacology, Toxicology and Therapeutic Chemistry.
- Jurado-Aguilar J, Barroso E, Bernard M, Zhang M, Peyman M, Rada P, Valverde ÁM, Wahli W, Palomer FX and Vazquez M GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-ß1/SMAD3 pathway. METABOLISM-CLINICAL AND EXPERIMENTAL . 152: 155772-155772.
- Peyman M, Barroso E, Turcu AL, Estrany F Jr, Smith D, Jurado-Aguilar J, Rada P, Morisseau C, Hammock BD, Valverde ÁM, Palomer FX, Galdeano C, Vázquez S and Vazquez M Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress BIOMEDICINE & PHARMACOTHERAPY . 168: 115667-115667.
- Barroso E, Díaz M, Reguera AC, Peyman M, Balsinde J, Jurado-Aguilar J, Zhang M, Rostami A, Palomer FX, Ibañez-Toda L and Vazquez M CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns CELL COMMUNICATION AND SIGNALING . 21(1): 326-326.
A team led by Dr. Manuel Vázquez-Carrera, from the Institut de Recerca Sant Joan de Déu and professor Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine (IBUB) of the UB, has conducted a review study on the Growth Differentiation Factor 15 (GDF15) -a protein expressed under physiological stress conditions- and its potential impact on the treatment for type 2 diabetes.